All companies
Givaudan logo

What smart money is saying about Givaudan

GIVN.SW

No fund has written a full thesis on Givaudan in our archive, but 2 fund letters report a position in it, most recently Acatis in November 2026.

Get an email when a fund buys, sells or pitches it

Summarize with Warren AI
2
Reported positions
0
Bought
0
Sold
4
Letters

Position history

Between Q2 2025 and Q4 2026, 2 fund letters reported a position in Givaudan, with no move described.

Fund letters reporting a position in Givaudan, by quarter
QuarterLettersBoughtSoldTheses
Q4 20261000
Q2 20251000

Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.

Fund activity · 2 positions

  • HoldsAcatis
    November 2026
    “Eli Lilly (+24.7%) impressed with revenue growth of 39%, driven by strong demand for the diabetes and weight-loss medi- cines Mounjaro and Zepbound. Management subsequently raised its full-year forecast. Givaudan (+20.3%) benefited from strong performance in the perfumery business (+13.5%).”
    Givaudan
  • HoldsTitan Wealth Global Blue Chip
    June 2025

    Listed in Titan Wealth Global Blue Chip’s reported holdings.

    Givaudan

Also mentioned · 2

These funds discuss Givaudan as a competitor, benchmark or comparable, without disclosing a position in it.

  • “IFF is poised to operationally resemble industry leader Givaudan.”
    Givaudan
  • MentionedTactile Fund
    March 2026
    “Robertet is controlled by the Maubert family, who have guided the company for four generations. From time to time, larger competitors like DSM Firmenich and Givaudan have attempted to take over Robertet, but the Mauberts have always resisted.”
    Givaudan

Read the letters behind these Givaudan positions

Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves, and to Warren AI, which reads all of them for you.

View plans→
Share this ledger